These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27233924)

  • 61. Occupational toxicology and the control of exposure to pharmaceutical agents at work.
    Binks SP
    Occup Med (Lond); 2003 Sep; 53(6):363-70. PubMed ID: 14514902
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A tiered asthma hazard characterization and exposure assessment approach for evaluation of consumer product ingredients.
    Maier A; Vincent MJ; Parker A; Gadagbui BK; Jayjock M
    Regul Toxicol Pharmacol; 2015 Dec; 73(3):903-13. PubMed ID: 26416168
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Drafting guidelines for occupational exposure to chemicals: the Dutch experience with the assessment of reproductive risks.
    Stijkel A; van Eijndhoven JC; Bal R
    Am J Ind Med; 1996 Dec; 30(6):705-17. PubMed ID: 8914717
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Setting occupational exposure limits for antimicrobial agents: A case study based on a quaternary ammonium compound-based disinfectant.
    Dotson GS; Lotter JT; Zisook RE; Gaffney SH; Maier A; Colvin J
    Toxicol Ind Health; 2020 Sep; 36(9):619-633. PubMed ID: 33241765
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
    Müller L; Mauthe RJ; Riley CM; Andino MM; Antonis DD; Beels C; DeGeorge J; De Knaep AG; Ellison D; Fagerland JA; Frank R; Fritschel B; Galloway S; Harpur E; Humfrey CD; Jacks AS; Jagota N; Mackinnon J; Mohan G; Ness DK; O'Donovan MR; Smith MD; Vudathala G; Yotti L
    Regul Toxicol Pharmacol; 2006 Apr; 44(3):198-211. PubMed ID: 16412543
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Permitted Daily Exposure Values: Application Considerations in Toxicological Risk Assessments.
    Ball DJ; Beierschmitt WP
    Int J Toxicol; 2020; 39(6):577-585. PubMed ID: 32794434
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Advances in assessing ingredient safety.
    Dourson ML; York RG
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 2():S112-8. PubMed ID: 27427210
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Review of "Implications of Hormesis for Industrial Hygiene".
    Brosseau LM
    Hum Exp Toxicol; 2002 Jul; 21(7):395. PubMed ID: 15497236
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Relevance of bioaccumulating substances in the TTC concept.
    Leeman WR; Rouhani-Rankouhi T; Vogels J; Krul L
    Regul Toxicol Pharmacol; 2016 Jun; 77():42-8. PubMed ID: 26921795
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides.
    Bercu JP; Galloway SM; Parris P; Teasdale A; Masuda-Herrera M; Dobo K; Heard P; Kenyon M; Nicolette J; Vock E; Ku W; Harvey J; White A; Glowienke S; Martin EA; Custer L; Jolly RA; Thybaud V
    Regul Toxicol Pharmacol; 2018 Apr; 94():172-182. PubMed ID: 29408293
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An enhanced tiered toxicity testing framework with triggers for assessing hazards and risks of commodity chemicals.
    Plunkett LM; Kaplan AM; Becker RA
    Regul Toxicol Pharmacol; 2010 Dec; 58(3):382-94. PubMed ID: 20709129
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Chemistry, manufacturing and exposure assessments to support generally recognized as safe (GRAS) determinations.
    Barraj L; Murphy M; Tran N; Petersen B
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 2():S99-S104. PubMed ID: 27389281
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Current Trends of Practices in Nonclinical Toxicology: An Industry Survey.
    Authier S; Brock WJ; Halpern W; Harris SN; Jones D; McGovern T; McGovern PD; Pugsley MK
    Int J Toxicol; 2021 Dec; 40(6):487-505. PubMed ID: 34569357
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Controlling cleaning agent residues in pharmaceutical manufacturing: A harmonized scientific strategy.
    Araya S; Pfister T; Blum K; Clemann N; Faltermann S; Wiesner L; Hawkins W; van de Gevel I; Versyck K
    Regul Toxicol Pharmacol; 2023 Aug; 142():105430. PubMed ID: 37308050
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
    J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Exposure assessments in reproductive and developmental toxicity testing: An IQ-DruSafe industry survey on current practices and experiences in support of exposure-based high dose selection.
    Andrews PA; McNerney ME; DeGeorge JJ
    Regul Toxicol Pharmacol; 2019 Oct; 107():104413. PubMed ID: 31229519
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Significance of ICH--toxicokinetics guidance and its practice--a useful approach for safety drug development].
    Tsuda M; Ohno Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1997; (115):1-14. PubMed ID: 9641814
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Development of an occupational exposure limit for n-propylbromide using benchmark dose methods.
    Stelljes ME; Wood RR
    Regul Toxicol Pharmacol; 2004 Oct; 40(2):136-50. PubMed ID: 15450717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.